空隙
发表于 2025-3-21 18:44:24
书目名称Group-Sequential Clinical Trials with Multiple Co-Objectives影响因子(影响力)<br> http://figure.impactfactor.cn/if/?ISSN=BK0388968<br><br> <br><br>书目名称Group-Sequential Clinical Trials with Multiple Co-Objectives影响因子(影响力)学科排名<br> http://figure.impactfactor.cn/ifr/?ISSN=BK0388968<br><br> <br><br>书目名称Group-Sequential Clinical Trials with Multiple Co-Objectives网络公开度<br> http://figure.impactfactor.cn/at/?ISSN=BK0388968<br><br> <br><br>书目名称Group-Sequential Clinical Trials with Multiple Co-Objectives网络公开度学科排名<br> http://figure.impactfactor.cn/atr/?ISSN=BK0388968<br><br> <br><br>书目名称Group-Sequential Clinical Trials with Multiple Co-Objectives被引频次<br> http://figure.impactfactor.cn/tc/?ISSN=BK0388968<br><br> <br><br>书目名称Group-Sequential Clinical Trials with Multiple Co-Objectives被引频次学科排名<br> http://figure.impactfactor.cn/tcr/?ISSN=BK0388968<br><br> <br><br>书目名称Group-Sequential Clinical Trials with Multiple Co-Objectives年度引用<br> http://figure.impactfactor.cn/ii/?ISSN=BK0388968<br><br> <br><br>书目名称Group-Sequential Clinical Trials with Multiple Co-Objectives年度引用学科排名<br> http://figure.impactfactor.cn/iir/?ISSN=BK0388968<br><br> <br><br>书目名称Group-Sequential Clinical Trials with Multiple Co-Objectives读者反馈<br> http://figure.impactfactor.cn/5y/?ISSN=BK0388968<br><br> <br><br>书目名称Group-Sequential Clinical Trials with Multiple Co-Objectives读者反馈学科排名<br> http://figure.impactfactor.cn/5yr/?ISSN=BK0388968<br><br> <br><br>
简洁
发表于 2025-3-21 21:40:10
http://reply.papertrans.cn/39/3890/388968/388968_2.png
FIN
发表于 2025-3-22 00:58:52
http://reply.papertrans.cn/39/3890/388968/388968_3.png
euphoria
发表于 2025-3-22 08:13:34
Interim Evaluation of Efficacy in Clinical Trials with Two Primary Endpoints,wo interventions based on two primary endpoints. In this situation, there are many procedures for controlling the Type I error rate. We discuss the simplest procedure, i.e., the weighted Bonferroni procedure which is commonly applied in practice. We evaluate the behavior of the sample size, power, a
爆炸
发表于 2025-3-22 09:43:39
http://reply.papertrans.cn/39/3890/388968/388968_5.png
B-cell
发表于 2025-3-22 12:53:59
Future Developments,her design features. This includes clinical trials with more than two interventions (e.g., dose-selection clinical trials): trials with time-to-event endpoints and trials with targeted subgroups and enrichment clinical trial designs. In Chap. ., we briefly discuss the issues in the design of these t
B-cell
发表于 2025-3-22 20:42:16
http://reply.papertrans.cn/39/3890/388968/388968_7.png
平息
发表于 2025-3-22 23:55:14
http://reply.papertrans.cn/39/3890/388968/388968_8.png
MENT
发表于 2025-3-23 02:32:12
Philanthropy and Settler Colonialismuss several decision-making frameworks for evaluating efficacy or futility based on boundaries using group-sequential methodology. We incorporate the correlations among the endpoints into the calculations for futility critical boundaries and evaluate the required sample sizes as a function of design
FICE
发表于 2025-3-23 07:10:36
http://reply.papertrans.cn/39/3890/388968/388968_10.png